Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Scott Kopetz, MD, PhD, on Encorafenib and Cetuximab: Impact on Quality of Life in BRAF V600E–Mutant Disease

Posted: Tuesday, January 28, 2020

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, talks about how the use of encorafenib plus cetuximab without a MEK inhibitor affects the overall toxicity of the regimen.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement